HOME

Applied Plasma Medicine Center Director
Eun Ha Choi.

  • Ladies and Gentlemen !!
    Applied Plasma Medicine Center (APMC) has been established by Global Research Development Center (GRDC) program between between Plasma Bioscience Research Center (PBRC), Kwangwoon University, Korea and INP, Leibniz institute, Germany, which is supported by Korean Government, based on the plasma biosciences, chemistry, electronics, plasma biomaterials, and medicines, which aims for creative development and commercialization of plasma medicine devices, especially for skin related diseases throughout global joint collaboration. Here the selective systemization and standardization of plasma medicine devices operated at atmospheric pressure are essential and fundamental topics to be developed throughout APMC joint center for their clinical applications to human beings as well as public healths.

    The research and development topics for APMC also include the fundamental interaction characteristics of the bioplasmas with animal’s and human being’s skin-related diseases based on the interdisciplinary cooperations with 7 University Hospitals in Korea to become world-class level institute for applied plasma medicine with highly competitiveness for plasma medicine by integrating the fundamental topics and formatting the infrastructures throughout world wide networkings. Hence new technology and fundamental researches will be performed in APMC by creating the great values in plasma medicine fields and contributing to human-being's health enhancement.
  • I would like to express my sincere thanks to Kwangwoon University, Leibniz INP institute, Seoul Metropolitan City, Korea Government, National Research Foundation of Korea, and PBRC research teams for their supports to APMC establishment. I could say to all of APMC friends that we will do our best for applied plasma medicine based on our sincearity and collaboration networks.

    Director, APMC
    Eun Ha Choi

Applied Plasma Medicine Center Director
K.-D. Weltmann.

  • Ladies and Gentlemen !!
    Leibniz-Institute for Plasma Science and Technology e.V - INP Greifswald The Institute is dedicated on the one hand to establish applications such as plasma surface technology and arc technology. On the other hand, it opens and supports new fields of application, such as the use of plasma in the context of energy-efficient and resource-saving technologies, in life sciences (especially in new areas such as plasma biology, plasma medicine, plasma pharmacology) and for the degradation of pollutants. According to the motto "from idea to prototype", the basic research is closely connected with the promotion of new applications. On the one hand, innovative approaches are pursued until proof of technical feasibility. On the other hand, current problems in plasma technology serve as a point of orientation and driving force for the targeted acquisition of knowledge on the fundamentals of plasma physics.

    Structure
    The Institute in Greifswald dates back to the "Forschungsstelle für Gasentladungsphysik" (Research Centre for Gas Discharge Physics) established by Paul Schulz in 1946 and hosted by the Akademie der Wissenschaften der DDR (Academy of Sciences of the GDR). When Paul Schulz moved to Berlin in 1949, Rudolf Seeliger became director of the research centre, which in 1950 was renamed "Institut für Gasentladungsphysik" (Institute for Gas Discharge Physics) and in 1969 assigned to the "Zentralinstitut für Elektronenphysik" (ZIE) (Central Institute for Electron Physics). On 31 December 1991, the Institute was formally dissolved.

    In the design of its range of services, the INP takes into account both the requirements in research and development and the market needs in industry. The Institute has all the competencies necessary for the implementation of modern plasma applications (plasma sources particularly at atmospheric pressure and for plasma systems, plasma processes and process control technologies for surface technologies and volume processes, as well as diagnosis and modelling for the analysis of basic processes in the various forms of discharge). These competencies are reflected in the scientific organizational units (Scientific Departments) and are incorporated into the current topics of the Research Divisions.
  • The main task of the INP Research Program Plasma Medicine is to realize basic research and application oriented research in the field of biomedical application of cold atmospheric plasma and to support and organize the transfer of research results both to clinical research and to industrial application. During the last years this research was generously fostered by research grants from the Federal Ministry of Education and Research as well as the Ministry of Education, Science and Culture of Mecklenburg-Western Pomerania. With this work, INP Greifswald was able to establish itself to one of the world’s leading centers of the innovative research field plasma medicine. This was acknowledged by the evaluation of the Leibniz Association in 2014, where the research program was ranked as “excellent”. This was among other things motivated by the fact that research outcomes of this research program “set international standards in this young research field”.

    Not least thanks to the systematic basic research mainly realized by the INP-adjunct Centre for Innovation Competence (ZIK) “plasmatis - Plasma plus cell” two fundamental insights on main mechanisms of plasma-cell and plasma-tissue interactions are identified:
    · Biological plasma effects are significantly caused by plasma induced changes of the liquid environment of cells, and
    · Biological plasma effects are dominated by reactive oxygen and nitrogen species generated in or transferred into liquid phases by plasma treatment.

    The highlight of application-oriented research in plasma medicine was the CE certification of the cold atmospheric plasma jet kinpen Med by neoplas tools GmbH in 2013, which was mainly based on INP research effort. Starting with the availability of this certified medical device, clinical plasma application has been growing at first for treatment of chronic wounds as well as pathogen-based diseases of skin. Based on this and in cooperation with neoplas tools GmbH, several research partnerships with clinics could be opened or consolidated in 2014 and 2015, among others with different clinics in Germany.

    Director, APMC
    K.-D. Weltmann